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MYELOMAWITH AL AMYLOIDOSIS: 10 YEARS EXPERIENCEWITH STEM
CELL TRANSPLANT
Silva, L.1, Weber, D.1, Wang, M.2, Han, E.2, Mendoza, F.2, de
Lima, M.1, Qazilbash, M.1, Champlin, R.E.1, Giralt, S.1 1The Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX; 2The Univer-
sity of Texas MD Anderson Cancer Center, Houston, TX.
Background: (AL) Amyloidosis is a rare and potentially fatal dis-
ease that involves deposition of light chain protein by a clonal
plasma cell population. Treatment with high dose melphalan and
autologous stem cell transplant (ASCT) can improve survival and
reverse organ damage, but this treatment is associated with toxicity
and mortality. We reviewed the outcome of patients with amyloid-
osis, who received hematopoietic stem cell transplant (HSCT) at
our institution.Patients andMethods:The retrospective study an-
alyzed 32 patients with AL Amyloidosis who underwent transplant
between 1997–2006. There were 17 men and 15 women, with a me-
dium age of 53 years (range 35–73 years). All patients had diagnostic
criteria for multiple myeloma (MM) and had biopsy confirmed am-
yloidosis of at least one organ site. Six patients had at least 1 organ
involved with AL amyloidosis (3 bone marrows, 2 subcutaneous and
1 kidney), 20 patients had 2 organs involved, while 6 patients had 3
or more organs affected. Twenty-eight patients underwent autolo-
gous transplant, while 4 had an allogeneic transplants (2 syngeneic
and 2 siblings). The preparative regimens received in 28 patients
were high dose melphalan (26 autologous and 2 syngeneic), 2 pa-
tients received Busulfan and Melphalan, 2 allogeneic transplant Flu-
darabine and Melphalan. Results: The median Charlson
Comorbidities Index (CCI) was 3 (range 0–8). The median number
of CD341 cells infused was 4.85  106 cells/kg (range 1.43–7.82
cells/kg). The median time to neutrophil and platelet engraftment
were 11 (range 2–21 days) and 14 days (range 2–41), respectively.
56% of patients developed moderate to severe gastrointestinal ef-
fects. Four patients underwent allogeneic transplant and 1 had acute
and chronic graft vs host disease (GVHD). Twenty-one patients
(65%) achieved a partial hematological remission (PR), and 5 pa-
tients (15%) achieved complete hematological remission (CR),
with a total response hematological rate of 80%. The 100 day
NRM was 3.2%. The median overall survival was (OS) 41 months
(range 1–108), 7 patients died (4 relapsed and 3 infections) all 7 pa-
tients had CCI greater or equal to 4. Conclusion: Selected patients
with MM and amyloidosis can benefit from high dose therapy with
stem cell support including allogeneic transplantation. The high
mortality seen in patients with CCI .4 suggests that this index
could be useful in selecting patients for high dose chemotherapy.92
LONGTERM FOLLOW-UP OF PATIENTS WITH SYSTEMIC AL AMYLOID-
OSIS TREATED WITH HIGH-DOSE MELPHALAN AFTER INDUCTION
AND MOBILIZATION CHEMOTHERAPY
Schonland, S.O., Bochtler, T., Hansberg, M., Mangatter, A., Perz, J.B.,
Hundemer, M., Ho, A.D., Goldschmidt, H., Hegenbart, U. University of
Heidelberg, Heidelberg, Germany.
Introduction: Longterm survival in AL amyloidosis (AL) pa-
tients (pts) without evidence of disease has been shown recently after
high-dose melphalan (HDM) (Sanchorawala, Blood 2007). How-
ever, no advantage of HDM compared to conventional chemother-
apy has been observed in a randomized multicenter trial (Jaccard,
NEJM 2007). This was probably due to high transplantation related
mortality (TRM) and a substantially longer time to the start of che-
motherapy in the HDM group. Whether treatment intensification
using induction and mobilization chemotherapy prior HDM can
improve results is not well investigated. Methods: We have up-
dated 23 pts with AL (Perz, BJH 2004) who received vincristine/
adriamycine/dexamethasone as induction and mobilization chemo-
therapy prior to HDM in our center from 1998 until 2004. Inclu-
sion criteria were age\ 70 years, NYHA stage\ III and a WHO
performance status\ 3. Median age was 57 years; median number
of involved organs was 3. Thirteen pts had symptomatic organ in-
volvement of heart and kidney, respectively (on dialysis at HDM,
n 5 4). The median follow-up after HDM is 66 months. Results:TRM was 9%. Prior HDM 14% of pts achieved a complete remis-
sion (CR). CR rate increased to 67% post HDM and organ response
(OR) was observed in 57%. The median overall survival (OS) has
not been reached. Pts with CR have an estimated OS of 90% after
6 years; for pts not reaching CR the median OS is 48 months (p
5 0.002). Hematological relapse occurred in 50%; 6 pts are still
in first CR with an OR. Discussion: We observed a very high CR
and OR rate using this intensive treatment approach. Pts with CR
have an excellent survival. Therefore, the role of induction therapy
in AL should be further investigated in randomized trials in experi-
enced centers. Results might be also improved incorporating new
drugs in induction and consolidation therapies. The main goal of
treatment in AL remains achievement and maintenance of a CR
of the underlying plasma cell disorder.93
AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION FOLLOWING
HIGH-DOSE AND SUPRALETHAL CHEMORADIOTHERAPY USING
STORED NONCRYOPRESERVED AUTOLOGOUS PERIPHERAL BLOOD IN
COLOMBIA
Cuervo-Sierra, J.1,2, Guzman-Zapata, A.1,2, Quevedo-Velez, A.1,2, Du-
que-Martelo, J.I.1,2, Mondragon, M.C.2, Cuellar-Ambrosi, F.1,2 1Hospi-
tal Universitario San Vicente de Paul, Medellın, Colombia; 2School of
Medicine-Universidad deAntioquia, Medellın, Colombia.
Although cryopreservation is the standard for autotransplanta-
tion, it has logistic and financial disadvantages in undeveloped
countries such as Colombia.
Between September 1993 and August 2007, in 72 patients, pe-
ripheral blood was refrigerated at 4C up to 144 hours before
autotransplantation. 41 men and 31 women of median age 37 years
affected with High-risk or relapsing non-Hodgkin lymphoma
(NHL) (n 5 27, 37.5%), multiple mieloma (MM) (n 5 21,
29.16%), relapsing Hodgkin disease (n 5 12, 16.6%), acute leuke-
mias (n 5 8, 11.1%), Langerhans cell histiocytosis (n 5 2, 2.8%),
breast cancer (n 5 1, 1.4%) and autoimmune disease (n 5 1,
1.4%) were mobilized with G-CSF only. Conditioning regimens
were: MEL 200 in 21 patients, CBV in 28 patients, Cy-TBI in 13
patients, BEAM/BEAC in 7 patients, Fludarabine-MEL-Alemtuzu-
mab in 3 patients.
The 17 patients in Group 1 showed pre-refrigeration CFU-GM
of 2.62  105/kg (range 0.36 to 16.6  105/kg) and at re-infusion
1.36  105/kg (range 0 to 6.32  105/kg) of 83% viability (range,
78% to 96%). These patients showed . 0.5  109/L granulocytes
on day 1 11 (range, 9 to 15) and .20  109/L platelets on day
116 (range, 11 to 44). The 49 patients in Group 2 showed CD34
of 5.4  106/kg (range, 0.16 to 17.1  106/kg) and mononuclear
cell count (MNC) of 8.7  108/kg, reaching .0.5  10 9/L granu-
locytes at day113 (range, 9 to 17) and.20 109/L platelets on day
115 (range, 10 to 40). Among the 6 patients in Group 3, the average
of MNC of 10.73  108/kg was reached and .0.5  109/L granu-
locytes on day 111 (range, 10 to 16) and .20  109/L platelets on
day114 (range, 10 to 18). No graft failure was observed. No differ-
ences were observed between the groups. At three and five years
51% are alive in complete remission.
Refrigeration of peripheral blood is a simple, effective, and inex-
pensive method that can be considered for autotransplants within
a few days of harvesting where resources are limited for long-term
storage.94
DELAYED PLATELET ENGRAFTMENT AND OUTCOME OF STEM CELL
TRANSPLANT FOR MULTIPLE MYELOMA: POSSIBLE MICROENVIRON-
MENT EFFECT?
Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K.,
Dingli, D., Rajkumar, S.V., Litzow, M.R., Gertz, M.A. Mayo Clinic,
Rochester, MN.
Background: Autologous stem cell transplantation (ASCT) is
an effective treatment modality for patients (pts) with multiple
